Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T R Jeffry Evans

Showing results (11-20 of 55) with videos related to

Pageof 6
Sort By:
Cancer Chemotherapy and Pharmacology|July 26, 2008
A multi-centre dose-escalation and pharmacokinetic study of diflomotecan in patients with advanced malignancyJanet S Graham, Stephen Falk, Leslie M Samuel, et al.
Molecular Cancer|November 26, 2009
Antiproliferative effect of exemestane in lung cancer cellsAngelos Koutras, Efstathia Giannopoulou, Ismini Kritikou, et al.
Tumori|May 3, 2011
Serum beta-HCG and CA-125 as tumor markers in a patient with osteosarcoma: case reportDavid S Boss, Hilary Glen, Jos H Beijnen, et al.
Drug Discovery Today|February 9, 2012
Cancer cell senescence: a new frontier in drug developmentClaire J Cairney, Alan E Bilsland, T R Jeffry Evans, et al.
Cancer Chemotherapy and Pharmacology|April 19, 2007
A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinomaRobert J Jones, Robert E Hawkins, Martin M Eatock, et al.
Cancer Chemotherapy and Pharmacology|May 14, 2014
A phase I and pharmacokinetic study of capecitabine in combination with radiotherapy in patients with localised inoperable pancreatic cancerPatricia Roxburgh, Graeme R Lumsden, James Paul, et al.
Future Oncology (London, England)|July 22, 2014
Plasma N-acetyl-glucosaminidase in advanced gastro-intestinal adenocarcinoma correlates with age, stage and outcomeDaniel Hartmann, Guido von Figura, Zhangfa Song, et al.
BMC Cancer|October 12, 2016
Phase II study of TP300 in patients with advanced gastric or gastro-oesophageal junction adenocarcinomaDavid Propper, Keith Jones, D Alan Anthoney, et al.
British Journal of Cancer|February 21, 2019
A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabineChris Twelves, Alan Anthoney, Claudio I Savulsky, et al.
Oncogene|January 25, 2003
Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductaseAlan E Bilsland, Claire J Anderson, Aileen J Fletcher-Monaghan, et al.
Pageof 6

Showing results (11-20 of 55) with videos related to

Sort By:
Pageof 6
Cancer Chemotherapy and Pharmacology|July 26, 2008
A multi-centre dose-escalation and pharmacokinetic study of diflomotecan in patients with advanced malignancyJanet S Graham, Stephen Falk, Leslie M Samuel, et al.
Molecular Cancer|November 26, 2009
Antiproliferative effect of exemestane in lung cancer cellsAngelos Koutras, Efstathia Giannopoulou, Ismini Kritikou, et al.
Tumori|May 3, 2011
Serum beta-HCG and CA-125 as tumor markers in a patient with osteosarcoma: case reportDavid S Boss, Hilary Glen, Jos H Beijnen, et al.
Drug Discovery Today|February 9, 2012
Cancer cell senescence: a new frontier in drug developmentClaire J Cairney, Alan E Bilsland, T R Jeffry Evans, et al.
Cancer Chemotherapy and Pharmacology|April 19, 2007
A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinomaRobert J Jones, Robert E Hawkins, Martin M Eatock, et al.
Cancer Chemotherapy and Pharmacology|May 14, 2014
A phase I and pharmacokinetic study of capecitabine in combination with radiotherapy in patients with localised inoperable pancreatic cancerPatricia Roxburgh, Graeme R Lumsden, James Paul, et al.
Future Oncology (London, England)|July 22, 2014
Plasma N-acetyl-glucosaminidase in advanced gastro-intestinal adenocarcinoma correlates with age, stage and outcomeDaniel Hartmann, Guido von Figura, Zhangfa Song, et al.
BMC Cancer|October 12, 2016
Phase II study of TP300 in patients with advanced gastric or gastro-oesophageal junction adenocarcinomaDavid Propper, Keith Jones, D Alan Anthoney, et al.
British Journal of Cancer|February 21, 2019
A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabineChris Twelves, Alan Anthoney, Claudio I Savulsky, et al.
Oncogene|January 25, 2003
Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductaseAlan E Bilsland, Claire J Anderson, Aileen J Fletcher-Monaghan, et al.
Pageof 6